Men’s health

  • Researchers have identified a gene signature in localized prostate cancer that predicts the cancer's odds of spreading and its response to a common treatment for advanced disease.
  • A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research. The feasibility study showed that 68Ga-PSMA CLI can image the entire excised prostate specimen's surface to detect prostate cancer tissue at the resection margin.
  • Researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings […]
  • An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial. The study showed that overall survival was 2 – 3 times higher than in the placebo arm.
  • An increased awareness on a molecular level of what mechanisms prostate cancer cells use to become mobile and start spreading may in the long run provide new opportunities for treatment of aggressive prostate cancer. This according to a new study by researchers at Umeå University, Sweden, in collaboration with researchers in Uppsala and Tokyo.